High throughput screening of orthosteric inhibitors of flavivirus protease

黄病毒蛋白酶正构抑制剂的高通量筛选

• 批准号: 10376239
• 负责人: HONGMIN LI
• 金额: $ 55万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-02-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10376239
• 关键词: Acquired Immunodeficiency Syndrome; Active Sites; Address; Affect; Affinity; Animals; Antiviral Agents; Antiviral Therapy; Arboviruses; Area; Binding; Biological Assay; Biological Availability; Biological Models; Cell Culture Techniques; Cells; Charge; Clinical; Complement; Complex; Dengue; Dengue Hemorrhagic Fever; Dengue Virus; Development Plans; Disease; Disease Outbreaks; Drug Kinetics; Drug Targeting; Ensure; Enzyme Inhibitor Drugs; Enzyme Interaction; Enzymes; Flavivirus; Flavivirus Infections; Fluorescence Resonance Energy Transfer; Generations; Genes; Goals; Growth; Hepatitis C; Infection; Japanese Encephalitis Vaccines; Japanese encephalitis virus; Lead; Libraries; Life; Luciferases; Mass Vaccinations; Meningitis; Microcephaly; Modeling; Multienzyme Complexes; Mus; Mutagenesis; Mutation; Outcome Study; Peptide Hydrolases; Persons; Pharmaceutical Preparations; Polyproteins; Populations at Risk; Prevention; Protease Inhibitor; Proteins; Public Health; Renilla Luciferases; Replicon; Research; Resistance; Resources; Site; Solid; Structure-Activity Relationship; System; Technology; Testing; Tick-Borne Encephalitis Virus; Toxic effect; Toxicity Tests; Vaccinated; Vaccines; Variant; Viral; Viral Genome; Viral Physiology; Viral Proteins; Virus; Virus Assembly; Virus Replication; West Nile Encephalitis; West Nile virus; Work; Yellow fever virus; ZIKA; Zika Virus; anti-viral efficacy; antiviral drug development; arthropod-borne; base; burden of illness; combat; drug development; drug discovery; efficacy evaluation; fighting; high throughput screening; human disease; human pathogen; in vivo; inhibitor; innovation; nanomolar; novel; public health priorities; screening; small molecule libraries; therapeutic target; therapy design; tool; vaccine development; viral resistance; virology

Project Summary/Abstract: Many flaviviruses such as Dengue virus, Zika virus, West Nile virus, and Yellow Fever virus cause significant human diseases. However, no clinically approved antiviral therapy is available for treatment of flavivirus infections. Therefore, the development of vaccines and antiviral agents for prevention and treatment of flavivirus infections is a clear public health priority. The long- range goal of this proposal is to address this need by developing a new system to identify, screen and validate a class of potential flavivirus inhibitors, and successfully identify and analyze candidate compounds that show promise in disrupting viral survival. During flaviviral infection of the host cell, a single viral polyprotein is synthesized from the viral genome. This polyprotein is cleaved into its component proteins by a combination of host cell proteases and a two-component viral protease, encoded in genes NS2B and NS3. The function of this viral protease is indispensable for virus assembly and replication. The objectives of this project are to develop innovative high throughput screening strategies to identify and characterize compounds that orthosterically inhibit the function of the critical protease NS2B- NS3. To achieve project objectives, in Specific Aim 1, we will develop and perform novel high- throughput screening primary, secondary, and tertiary assays capable of screening large chemical libraries to identify orthosteric inhibitors. In Specific Aim 2, after optimizing these assays, we will perform large-scale HTS to screen a compound library of >400,000 compounds for potential protease inhibitor candidates, employing five levels of screening to fully eliminate false positives. In Specific Aim 3, we will evaluate the efficacy of the resulting candidate compounds for their capacity to block protease activity, and determined their modes of actions. Lead compounds against the protease will be tested for cellular toxicity, reduction of flavivirus titer in cell culture, resistant variants, and limited structure-activity relationship. We will ultimately test the toxicity, pharmacokinetics, and efficacy in live animals for the most potent compounds. We anticipate the outcome of this study will be the generation of crucial new information on flavivirus inhibitor-enzyme interaction at structurally significant sites. This creates the potential for identifying novel classes of flaviviral inhibitors, suitable for addressing the global public health need for new antiviral agents to fight flaviviruses.

项目概要/摘要： 许多黄病毒，如登革热病毒、寨卡病毒、西尼罗河病毒和黄热病病毒 导致严重的人类疾病。然而，没有临床批准的抗病毒治疗是可用的 用于治疗黄病毒感染。因此，疫苗和抗病毒剂的开发 预防和治疗黄病毒感染显然是公共卫生的优先事项。很长的- 本提案的范围目标是通过开发一个新系统来满足这一需求， 筛选并验证了一类潜在的黄病毒抑制剂，并成功鉴定和 分析有望破坏病毒存活的候选化合物。 在宿主细胞的黄病毒感染期间，从病毒多聚蛋白合成单个病毒多聚蛋白。 基因组这种多聚蛋白被宿主细胞的组合切割成其组成蛋白。 蛋白酶和双组分病毒蛋白酶，其在基因NS 2B和NS 3中编码。功能 这种病毒蛋白酶是病毒组装和复制所不可缺少的。这一目标 项目是开发创新的高通量筛选策略，以确定和 表征正构抑制关键蛋白酶NS 2B-的功能的化合物， NS3。 为了实现项目目标，在具体目标1中，我们将开发和执行新的高- 通量筛选一级、二级和三级试验，能够筛选大的 化学文库来鉴定正构抑制剂。在具体目标2中，在优化这些之后， 我们将进行大规模的HTS，以筛选超过40万种化合物的化合物库。 对于潜在的蛋白酶抑制剂候选物，采用五个级别的筛选，以完全消除 假阳性在具体目标3中，我们将评估最终候选人的有效性 化合物阻断蛋白酶活性的能力，并确定其作用模式。 将测试针对蛋白酶的先导化合物的细胞毒性、黄病毒减少 细胞培养物中的滴度、抗性变体和有限的结构-活性关系。最终肯定我们会 在活体动物中测试最有效化合物的毒性、药代动力学和功效。 我们预计这项研究的结果将是产生关键的新信息， 在结构上重要的位点上的黄病毒介导物-酶相互作用。这就创造了 用于鉴定新的黄病毒抑制剂类别，适用于全球公众 健康需要新的抗病毒药物来对抗黄病毒。

项目成果

Calcimycin Inhibits Cryptococcus neoformans In Vitro and In Vivo by Targeting the Prp8 Intein Splicing.

• DOI: 10.1021/acsinfecdis.2c00137
• 发表时间: 2022-09-09
• 期刊: ACS INFECTIOUS DISEASES
• 影响因子: 5.3
• 作者: Tharappel, Anil Mathew;Li, Zhong;Zhu, Yan Chun;Wu, Xiangmeng;Chaturvedi, Sudha;Zhang, Qing-Yu;Li, Hongmin
• 通讯作者: Li, Hongmin

Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease.

• DOI: 10.1016/j.antiviral.2017.12.018
• 发表时间: 2018-03
• 期刊: Antiviral research
• 影响因子: 7.6
• 作者: Li Z;Sakamuru S;Huang R;Brecher M;Koetzner CA;Zhang J;Chen H;Qin CF;Zhang QY;Zhou J;Kramer LD;Xia M;Li H
• 通讯作者: Li H

Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo.

• DOI: 10.1080/22221751.2020.1838954
• 发表时间: 2020-12
• 期刊: Emerging microbes & infections
• 影响因子: 13.2
• 作者: Li Z;Lang Y;Sakamuru S;Samrat S;Trudeau N;Kuo L;Rugenstein N;Tharappel A;D'Brant L;Koetzner CA;Hu S;Zhang J;Huang R;Kramer LD;Butler D;Xia M;Li H
• 通讯作者: Li H

In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus.

• DOI: 10.1016/j.apsb.2021.10.017
• 发表时间: 2022-04
• 期刊: ACTA PHARMACEUTICA SINICA B
• 影响因子: 14.5
• 作者: Li, Zhong;Xu, Jimin;Lang, Yuekun;Wu, Xiangmeng;Hu, Saiyang;Samrat, Subodh Kumar;Tharappel, Anil M.;Kuo, Lili;Butler, David;Song, Yongcheng;Zhang, Qing-Yu;Zhou, Jia;Li, Hongmin
• 通讯作者: Li, Hongmin

JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo.

• DOI: 10.1021/acsinfecdis.0c00217
• 发表时间: 2020-10-09
• 期刊: ACS infectious diseases
• 影响因子: 5.3
• 作者: Li Z;Xu J;Lang Y;Fan X;Kuo L;D'Brant L;Hu S;Samrat SK;Trudeau N;Tharappel AM;Rugenstein N;Koetzner CA;Zhang J;Chen H;Kramer LD;Butler D;Zhang QY;Zhou J;Li H
• 通讯作者: Li H